Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus | Zendy

Nathan P. Wiederhold | Zendy; Laura K. Najvar | Zendy; Rosie Jaramillo | Zendy; Marcos Olivo | Zendy; Brian L. Wickes | Zendy; Gabriel Catano | Zendy; Thomas F. Patterson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus

Author(s) -

Nathan P. Wiederhold,

Laura K. Najvar,

Rosie Jaramillo,

Marcos Olivo,

Brian L. Wickes,

Gabriel Catano,

Thomas F. Patterson

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01165-19

Subject(s) - posaconazole , aspergillus fumigatus , aspergillosis , echinocandin , azole , dosing , anidulafungin , medicine , aspergillus , pharmacology , biology , itraconazole , microbiology and biotechnology , voriconazole , antifungal , caspofungin , fluconazole , immunology

We evaluated extended-interval dosing of the investigational echinocandin rezafungin (1, 4, and 16 mg/kg on days 1, 4, and 7 postinoculation) for the treatment of disseminated invasive aspergillosis caused by azole-resistant Aspergillus fumigatus Survival was significantly improved in mice treated with each dose of rezafungin and supratherapeutic posaconazole (20 mg/kg twice daily). Kidney fungal burden, as measured by quantitative real-time PCR, was also significantly reduced in mice treated with rezafungin although variability was observed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research